Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.

Hage C, Hoves S, Ashoff M, Schandl V, Hört S, Rieder N, Heichinger C, Berrera M, Ries CH, Kiessling F, Pöschinger T.

PLoS One. 2019 Jul 10;14(7):e0219517. doi: 10.1371/journal.pone.0219517. eCollection 2019.


Molecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles.

Cianciaruso C, Beltraminelli T, Duval F, Nassiri S, Hamelin R, Mozes A, Gallart-Ayala H, Ceada Torres G, Torchia B, Ries CH, Ivanisevic J, De Palma M.

Cell Rep. 2019 Jun 4;27(10):3062-3080.e11. doi: 10.1016/j.celrep.2019.05.008.


Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.

Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Pöschinger T, Kiessling F, Ries CH.

Hepatology. 2019 Oct;70(4):1280-1297. doi: 10.1002/hep.30666. Epub 2019 May 21.


Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY, Ooi CH, Rüttinger D, Cassier PA, Jonkers J, Schultze JL, Ries CH, de Visser KE.

Nat Cell Biol. 2019 Apr;21(4):511-521. doi: 10.1038/s41556-019-0298-1. Epub 2019 Mar 18.


Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses.

Cubas R, Moskalenko M, Cheung J, Yang M, McNamara E, Xiong H, Hoves S, Ries CH, Kim J, Gould S.

J Immunol. 2018 Oct 15;201(8):2273-2286. doi: 10.4049/jimmunol.1800275. Epub 2018 Sep 12.


T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.


Periostin Limits Tumor Response to VEGFA Inhibition.

Keklikoglou I, Kadioglu E, Bissinger S, Langlois B, Bellotti A, Orend G, Ries CH, De Palma M.

Cell Rep. 2018 Mar 6;22(10):2530-2540. doi: 10.1016/j.celrep.2018.02.035.


Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, De Palma M, Rüttinger D, Ries CH.

J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.


Effects of IL-10 and Th 2 cytokines on human Mφ phenotype and response to CSF1R inhibitor.

Pradel LP, Franke A, Ries CH.

J Leukoc Biol. 2018 Mar;103(3):545-558. doi: 10.1002/JLB.5MA0717-282R. Epub 2018 Jan 4.


A drug development perspective on targeting tumor-associated myeloid cells.

Majety M, Runza V, Lehmann C, Hoves S, Ries CH.

FEBS J. 2018 Feb;285(4):763-776. doi: 10.1111/febs.14277. Epub 2017 Oct 19. Review.


Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.

Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D.

J Immunother Cancer. 2017 Jul 18;5(1):53. doi: 10.1186/s40425-017-0257-y. Review.


An Immune Atlas of Clear Cell Renal Cell Carcinoma.

Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B.

Cell. 2017 May 4;169(4):736-749.e18. doi: 10.1016/j.cell.2017.04.016.


T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.


T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.


Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.

Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Rüttinger D, Ries CH.

Mol Cancer Ther. 2016 Dec;15(12):3077-3086. Epub 2016 Aug 31.


Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity.

Baer C, Squadrito ML, Laoui D, Thompson D, Hansen SK, Kiialainen A, Hoves S, Ries CH, Ooi CH, De Palma M.

Nat Cell Biol. 2016 Jul;18(7):790-802. doi: 10.1038/ncb3371. Epub 2016 Jun 13.


XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.

Schanzer JM, Wartha K, Moessner E, Hosse RJ, Moser S, Croasdale R, Trochanowska H, Shao C, Wang P, Shi L, Weinzierl T, Rieder N, Bacac M, Ries CH, Kettenberger H, Schlothauer T, Friess T, Umana P, Klein C.

MAbs. 2016 May-Jun;8(4):811-27. doi: 10.1080/19420862.2016.1160989. Epub 2016 Mar 16.


Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

Galletti G, Scielzo C, Barbaglio F, Rodriguez TV, Riba M, Lazarevic D, Cittaro D, Simonetti G, Ranghetti P, Scarfò L, Ponzoni M, Rocchi M, Corti A, Anselmo A, van Rooijen N, Klein C, Ries CH, Ghia P, De Palma M, Caligaris-Cappio F, Bertilaccio MTS.

Cell Rep. 2016 Feb 23;14(7):1748-1760. doi: 10.1016/j.celrep.2016.01.042. Epub 2016 Feb 11.


Fibroblasts Influence Survival and Therapeutic Response in a 3D Co-Culture Model.

Majety M, Pradel LP, Gies M, Ries CH.

PLoS One. 2015 Jun 8;10(6):e0127948. doi: 10.1371/journal.pone.0127948. eCollection 2015.


CSF-1/CSF-1R targeting agents in clinical development for cancer therapy.

Ries CH, Hoves S, Cannarile MA, Rüttinger D.

Curr Opin Pharmacol. 2015 Aug;23:45-51. doi: 10.1016/j.coph.2015.05.008. Epub 2015 Jun 4. Review.


Targeting tumor-associated macrophages in cancer therapy and understanding their complexity.

Cannarile MA, Ries CH, Hoves S, Rüttinger D.

Oncoimmunology. 2014 Dec 13;3(9):e955356. eCollection 2014 Oct.


Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.


GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.


In vitro generation of monocyte-derived macrophages under serum-free conditions improves their tumor promoting functions.

Rey-Giraud F, Hafner M, Ries CH.

PLoS One. 2012;7(8):e42656. doi: 10.1371/journal.pone.0042656. Epub 2012 Aug 6.


Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.

Pickl M, Ries CH.

Oncogene. 2009 Jan 22;28(3):461-8. doi: 10.1038/onc.2008.394. Epub 2008 Nov 3.


Supplemental Content

Support Center